The $11 Billion Gamble the Market Hated

On November 21, 2011, Gilead Sciences announced it would buy Pharmasset, a clinical-stage company in Princeton with no marketed product, for $137.00 a share in cash — roughly $11 billion, an 89% premium.1 Gilead's own shares fell about 6% on the news; analysts called it a gamble, and on the arithmetic of the moment they were right. Gilead was paying eleven figures for a single molecule that had not yet been approved for anything. The deal closed in January 2012.

This is the mirror image of the case next door. Where Bristol Myers bought proven revenue and watched a contingent payout evaporate, Gilead bought an unproven pipeline and watched it become the most successful drug launch in history. Grade either one on a single metric and you will be wrong — just in opposite directions. So, again, two grades: was the bet reasonable at the price, and did the outcome pay?

The thesis they sold

Gilead bought essentially one thing: PSI-7977, an unpartnered uracil nucleotide analog — later sofosbuvir — that had just entered Phase 3 for hepatitis C. Not a portfolio, not a hedge. A concentrated wager that a single once-daily pill could anchor an all-oral, interferon-free cure. The structure matched the conviction: all cash, no financing condition, guided dilutive through 2014 and accretive after. The market read concentration as fragility. Gilead read it as the whole point of paying up.

The asset's fate — a launch, and a windfall

Sofosbuvir was approved as Sovaldi on December 6, 2013; Harvoni followed in 2014 and Epclusa in 2016.2 Gilead priced a 12-week course at $84,000 — $1,000 per pill — a number that, per the later Senate investigation, Pharmasset's own internal models had contemplated at closer to $36,000.5 The pricing was built to maximize revenue, and it did. The purchase price of the entire company was recovered inside the first year the drug was on the market.

Set this against the BMS timeline and the contrast is the entire method. There, a 36-day slip took a $6.4B payout to zero. Here, the acquired molecule returned its own purchase price before the ink was dry on the integration.

Did it pay — the paradox

And then the revenue fell — hard. The franchise peaked near $19.1 billion in 2015 and slid to about $3.7 billion by 2018.3 On a Revlimid-style reading that looks like a collapse. It is the opposite. Sovaldi and its successors cured people; a cure shrinks its own market by design, treating the prevalent pool down toward the smaller annual flow of new infections. The decline is the product succeeding, not failing — and across roughly five years the franchise still returned on the order of $58 billion on an $11 billion outlay.4

As with the deal next door, the accounting never flinched: Gilead recorded no goodwill impairment on the Pharmasset acquisition. Its later write-downs attached to other deals entirely. The one transaction that supposedly over-relied on a self-limiting franchise produced no accounting confession — because there was nothing to confess.

Did it pay — the market

Acquirer total return misleads here too, in the reverse direction. Gilead's stock ran up roughly five- to six-fold into a 2015 peak, then declined for years as the HCV franchise shrank — and its recovery toward the mid-$120s by 2026 has been driven by HIV, not hepatitis C. An investor reading only the post-2015 share chart would conclude the deal soured. It did not; the share price simply reflects a self-liquidating windfall plus the rest of a large company. The market's initial 6% verdict on announcement was as wrong as a market verdict gets.

The context

Two shadows fall across an otherwise pristine result. First, price and access: the bipartisan Wyden-Grassley Senate Finance investigation, drawing on some 20,000 pages of internal documents, concluded the $84,000 price was set to maximize revenue with little regard for access, and state Medicaid programs rationed treatment — Oregon, for one, capped the number of patients treated per year.5 Second, litigation: a Delaware jury handed Merck's subsidiary Idenix $2.54 billion in 2016 — then the largest U.S. patent verdict ever — for infringement, before the underlying patent was ruled invalid and the Federal Circuit affirmed for Gilead in 2019.6 Merck had paid $3.85 billion for Idenix in 2014; the verdict, and then the reversal, were their own multi-billion-dollar round trip.

The yardstick

Same fact — "the revenue fell" — opposite meaning. On one deal it is the cliff arriving; on this one it is the cure working.

The honest grade is, once more, the two-grade one. The bet earns an A: an 89% premium for a pre-approval asset is exactly the kind of decision that looks indefensible until you are right, and Gilead was right because it concentrated on the single best molecule and structured the deal to move fast. The outcome is an A−, not an A, and the missing sliver is not financial — the cash economics are historic — but reputational and structural: a pricing-and-access controversy that reshaped the drug-pricing debate for a decade, a $2.5B litigation scare, and a windfall that by its own curative nature could not compound. A nearly perfect deal, with an asterisk it earned.

Method

Every retrospective here reconstructs a deal from free primary documents — SEC filings, Drugs@FDA, congressional records, court opinions, company disclosures — and assigns two grades: Bet (was it reasonable at the price?) and Outcome (did it pay?), each judged by the yardstick that actually fits the deal. Grades are the author's judgment, defensible but arguable; the underlying figures are sourced below.

Retrospective analysis of public information for educational purposes; not investment advice. Figures are rounded from public reporting — confirm exact values in the underlying filings before relying on them. Views are the author's own and not those of any employer.